SCHEMBL71589

SCHEMBL71589

CC(=O)ON1CC(C)OC(C)C1

nearest known ligand 0.39

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
TSHR P16473 1/20 0.37
ALDH1A1 P00352 5/20 0.37
NPC1 O15118 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
HSD17B10 Q99714 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
PDK1 Q15118 1/20 0.36
HPGD P15428 4/20 0.36
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP2C19 P33261 1/20 0.34
LMNA P02545 1/20 0.34
KDM4E B2RXH2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL715535 0.76 PDK1 (0.40) TSHRL3MBTL1PDK1MEN1KMT2A
SCHEMBL7707567 0.76 KMT2A (0.37) TSHRALDH1A1HPGDMEN1KMT2A
SCHEMBL29062240 0.75
SCHEMBL8137649 0.75
SCHEMBL4000982 0.70 SMN1; SMN2 (0.52) PKMMAPK1SMN1; SMN2ALDH1A1NPC1
SCHEMBL1196644 0.70 SMN1; SMN2 (0.52) PKMMAPK1SMN1; SMN2ALDH1A1NPC1
SCHEMBL20671801 0.70 SMN1; SMN2 (0.52) PKMMAPK1SMN1; SMN2ALDH1A1NPC1
SCHEMBL18478123 0.70 SMN1; SMN2 (0.52) PKMMAPK1SMN1; SMN2ALDH1A1NPC1
SCHEMBL13665465 0.69 PDK1 (0.38) SMN1; SMN2ALDH1A1NPC1NPSR1HSD17B10
SCHEMBL31591139 0.68 ALDH1A1 (0.37) TSHRALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-10120664-A None JP disclosed
EP-1961750-B1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO CO LTD (JP) 2013-09-18 EP disclosed
US-20130065882-A1 VLA-4 inhibitory drug MACHINAGA NOBUO (JP) 2013-03-14 US disclosed
US-20120157437-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-06-21 US disclosed
US-8129366-B2 VLA-4 inhibitory drug DAIICHI SANKYO COMPANY, LIMITED (JP) 2012-03-06 US disclosed
US-20090233901-A1 VLA-4 INHIBITORY DRUG DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-09-17 US disclosed
EP-1961750-A1 VLA-4 INHIBITORY DRUG Daiichi Sankyo Company, Limited (JP) 2008-08-27 EP disclosed
JP-H10120664-A NEW PERFLUORO(2,6-DIMETHYLMORPHOLINOACETYL FLUORIDE) AND ITS PRODUCTION AGENCY OF IND SCIENCE & TECHNOL 1998-05-12 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120157437-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 PKM 4083/4885MAPK1 1769/4885SMN1; SMN2 4739/4885
US-20130065882-A1 VLA-4 inhibitory drug VCAM1, ITGB4, ITGA4 PKM 4112/4885MAPK1 1875/4885SMN1; SMN2 4702/4885
US-20090233901-A1 VLA-4 INHIBITORY DRUG VCAM1, ITGB4, ITGA4 PKM 4337/4885MAPK1 1626/4885SMN1; SMN2 4787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.